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ABSTRACT
Multiple myeloma (MM)-associated osteolytic bone disease is a major cause 
of morbidity and mortality in MM patients and the development of new therapeutic 
strategies is of great interest. The proto-oncogene SRC is an attractive target for such 
a strategy. In the current study, we investigated the effect of treatment with the 
SRC inhibitor saracatinib (AZD0530) on osteoclast and osteoblast differentiation and 
function, and on the development of MM and its associated bone disease in the 5TGM.1 
and 5T2MM murine MM models. In vitro data showed an inhibitory effect of saracatinib 
on osteoclast differentiation, polarization and resorptive function. In osteoblasts, 
collagen deposition and matrix mineralization were affected by saracatinib. MM cell 
proliferation and tumor burden remained unaltered following saracatinib treatment 
and we could not detect any synergistic effects with drugs that are part of standard 
care in MM. We observed a marked reduction of bone loss after treatment of 
MM-bearing mice with saracatinib as reflected by a restoration of trabecular bone 
parameters to levels observed in naive control mice. Histomorphometric analyses 
support that this occurs through an inhibition of bone resorption. In conclusion, 
these data further establish SRC inhibition as a promising therapeutic approach for 
the treatment of MM-associated osteolytic bone disease.
INTRODUCTION
Multiple myeloma (MM) is the second most 
common hematological malignancy and accounts for 
approximately 1% of all cancers and 2% of all deaths 
from cancer. In the past decades, therapeutic advances 
have been made by introducing hematopoietic stem 
cell transplantation and new targeted molecules such as 
immune-modulatory agents, proteasome inhibitors and 
monoclonal antibodies. Unfortunately, MM remains an 
incurable disease with a 10-year survival of approximately 
30% in patients under 60 years [1]. MM is characterized 
by the clonal proliferation and accumulation of malignant 
plasma cells in the bone marrow (BM), monoclonal serum 
protein and associated organ dysfunction [2]. Underlying 
these changes are the oncogenic transformation of plasma 
cells and an associated altered BM microenvironment that 
further supports MM development [3].
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A major cause of morbidity and mortality in MM 
is the development of bone destructive lesions due to 
osteolytic bone disease, which occurs in more than 
80% of MM patients. These lesions can be extensive 
and cause severe bone pain, hypercalcemia, spinal 
cord compression and pathologic fractures that require 
radiation or surgical intervention. It is estimated that 50% 
of patients develop pathologic fractures over the course 
of their disease, increasing the risk of death by more than 
20% compared to patients without fractures [4, 5]. MM-
associated osteolytic bone disease is characterized by 
increased osteoclastogenesis and suppression of osteoblast 
function. This occurs via multiple mechanisms, including 
the secretion of osteoclastogenic factors and osteoblast-
inhibitory factors by both MM cells and stromal cells 
in the MM microenvironment. As a result, the bone 
remodeling process is uncoupled culminating in bone loss 
and lytic lesions [6-8].
The proto-oncogene c-SRC (SRC), a member of the 
SRC family of protein tyrosine kinases (SFKs), is a non-
receptor tyrosine kinase that mediates signal transduction 
from a diverse set of cell surface receptors in a wide 
range of cellular processes, including proliferation, 
differentiation, motility, adhesion and survival [9, 10]. 
SRC has been suggested to play an equally important 
role in osteoclasts and osteoblasts. SRC levels increase 
during osteoclast differentiation and SRC is important 
for the formation of actin rings in mature osteoclasts 
[11, 12]. Contrary to osteoclasts, SRC levels appear to 
decrease during osteoblast differentiation [13, 14]. As a 
result, depletion of SRC expression enhances osteoblast 
differentiation and bone formation [15]. These findings 
correspond with the osteopetrotic phenotype observed in 
SRC-/- mice [16], which display hepatosplenomegaly and 
develop odontomas with age [17].
As described, MM-associated osteolytic bone 
disease not only has a negative impact on the quality of 
life but also results in morbidity and adversely impacts 
overall survival of MM patients. Bisphosphonates remain 
the standard of care for MM-associated osteolytic bone 
disease and slow the progression of osteolytic lesions, 
prevent the development of pathologic fractures and may 
have additional limited anti-tumor effects in MM [18]. 
Interestingly, recent reports suggest that bisphosphonates 
act in part by inhibiting SRC expression [19] or modulating 
SRC signaling [20]. However, bisphosphonate use can 
have adverse side effects such as renal impairment, the 
development of atypical fractures and avascular necrosis 
of the jaw. Similar adverse effects were observed with 
novel targeted drugs such as the monoclonal receptor 
activator of nuclear factor κB ligand (RANKL)-antibody 
denosumab [21]. Moreover, skeletal-related events 
still occur in approximately 25% of patients receiving 
bisphosphonate therapy [22]. Thus, the development 
of new therapeutic strategies for this MM-related bone 
disease is of great interest. SRC is a promising target 
for such a strategy, given its important role in osteoclast 
and osteoblast function. Saracatinib is an orally available 
ATP-competitive SRC inhibitor which has been shown 
to hamper osteoclast function. In the current study, we 
investigated the effect of saracatinib on osteoclast and 
osteoblast function, and on the development of MM and 
its associated osteolytic bone disease.
RESULTS
Expression of SRC family kinases in the multiple 
myeloma microenvironment
Saracatinib (Figure 1A) is a potent SRC inhibitor 
with an IC50 of 2.7 nM in cell-free assays [23]. Aside 
SRC, other SFKs are potentially targeted by this 
compound, including Lymphocyte Cell-Specific Protein-
Tyrosine Kinase (LCK, 4 nM), Yamaguchi Sarcoma 
Oncogene (c-YES, 4 nM), Lck/Yes-Related Novel 
Protein Tyrosine Kinase (LYN, 5 nM), FYN Proto-
Oncogene, SFK (FYN, 10 nM), Feline Gardner-Rasheed 
Sarcoma Viral Oncogene Homolog (FGR, 10 nM) 
and B Lymphoid Tyrosine Kinase (BLK, 11 nM). We 
assessed the expression of these SFKs in MM cells. We 
first determined their expression in MM cells in a large 
cohort of MM patients (n = 162) at different stages of the 
disease. Except Lyn, all SFKs are expressed at low levels 
in MM cells (Figure 1B). Barring a few exceptions, SFKs 
mRNA expression generally does not change during MM 
progression. These findings were corroborated by analysis 
of SFK protein levels in different MM cell lines, i.e. U266, 
RPMI-8226, LP-1 and Karpas707. If available, these data 
show very low to absent protein expression of SFKs in 
MM cell lines compared to cells of different origin (Figure 
1B). We also performed SFKs expression analysis on 
publically available microarray data of osteoclast and 
osteoblast differentiation. We observed a marked increase 
in Src expression during osteoclast differentiation, while 
Fgr expression levels moderately increased. Other SFKs 
were expressed at very low levels (Supplementary Figure 
S1A). During the differentiation from mesenchymal stem 
cells to fully differentiated osteoblasts, Fyn expression 
levels slightly increased. Conversely, Src mRNA levels 
decreased at day 14, followed by a return to initial levels 
in fully matured osteoblasts at day 21. Osteoblasts also 
expressed Yes and Lyn (Supplementary Figure S1B).
Saracatinib inhibits RAW264.7 and primary 
osteoclast differentiation and bone resorption
Saracatinib treatment has previously been linked 
to decreased osteoclastogenesis and function. Here, we 
elaborated on and confirmed these findings. We first assessed 
whether saracatinib influences RAW264.7 proliferation 
and found no such effect over a range of concentrations 
after 3 days of culture (Figure 2A). Next, we confirmed an 
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inhibitory effect of saracatinib on osteoclast generation by 
TRAP staining. We observed a concentration-dependent 
decrease in the number of osteoclasts, i.e. TRAP-positive 
cells with at least 3 nuclei, which already became apparent 
at 0.1 μM (Figure 2B and 2C). These findings were 
confirmed on primary murine osteoclasts (Figure 2D and 
2E). Although lower concentrations of saracatinib did not 
affect cell survival, 10 μM appeared toxic in RANKL-
stimulated cultures. Src, Nfatc1 and Trap expression levels 
were not affected by saracatinib (Figure 2F). Conversely, 
saracatinib treatment resulted in a decreased expression of 
Ctsk and Dc-stamp and an increased expression of Mmp-9 
compared to DMSO-treated osteoclast cultures (Figure 2F). 
These changes culminated in defective matrix resorption by 
osteoclasts following saracatinib treatment (Figure 2G), as 
reflected in the total number of resorption pits (Figure 2H) 
and the average resorption pit size (Figure 2I). The inhibition 
of matrix resorption was already apparent after 0.1 μM 
saracatinib treatment, even though osteoclasts displayed a 
normal morphology at this concentration, and a complete 
inhibition of resorption was observed at concentrations > 
1 μM. This inhibitory effect on matrix resorption was also 
confirmed on primary murine osteoclasts (Figure 2J, 5K and 
2L). Finally, we found that actin ring formation is blocked 
after treatment with 1 μM saracatinib (Figure 2M).
Saracatinib decreases collagen deposition and 
affects matrix mineralization by osteoblasts
Whether saracatinib has a direct effect on 
osteoblast function has not yet been explored. 
We addressed this in vitro on the murine calvarial 
MC3T3-E1 cell line, a suitable model to study osteoblast 
differentiation and function [24], and on primary murine 
mesenchymal stem cell (MSC)-derived osteoblast 
cultures. We found that proliferation of MC3T3-E1 
cells is hampered when treated with pharmacologically 
relevant saracatinib concentrations, i.e. a decrease of 
31% relative absorbance on day 14 with a concentration 
of 1 μM saracatinib or lower versus controls (Figure 
3A). No such an effect could be observed on primary 
MSCs (Figure 3B). Next, we investigated the effect of 
1 μM saracatinib on osteoblast collagen deposition and 
matrix mineralization by Sirius red staining and Von 
Kossa staining, respectively (Figure 3C). Osteoblast 
size appeared increased in saracatinib-treated cultures 
and coincided with drastically decreased collagen 
deposition (Figure 3D). The total degree of matrix 
mineralization remained unaltered in MC3T3-E1 
osteoblast cultures (Figure 3E) although the pattern of 
mineralization appeared different in saracatinib-treated 
cultures with less discerned nodules. Conversely, 
matrix mineralization markedly increased in MSC 
osteoblast cultures (Figure 3E). We found a dose 
dependent inhibitory effect of saracatinib on MC3T3-E1 
migration (Figure 3F). Finally, we assessed the effect 
of saracatinib on osteoblast marker gene expression 
in MC3T3-E1 cells and observed a decrease of Osx 
and Ocn expression. In addition, Col1a1 expression 
was diminished, although this did not reach statistical 
significance. Saracatinib treatment did not alter Src, 
Runx2 or Alp expression (Figure 3G).
Figure 1: Expression of SRC family kinases in multiple myeloma cells. A. Chemical structure of saracatinib (4-Quinazolinamine, 
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)-quinazolin-4-amine) 
(image source: selleckchem.com). B. SFK mRNA expression in patients (GSE6477 dataset, total n=162 patients): Normal (healthy controls, 
n=15), MGUS (monoclonal gammopathy of undetermined significance, n=21), smoldering MM (n=23), newly diagnosed MM (n=75) and 
relapsed MM (n=28)(upper panel, *: p<.0.05 versus normal). SFK protein levels in MM cell lines (proteinatlas.org, lower panel). N.D.: not 
determined. Y-axis is kept at 0-8000 to illustrate the protein expression range in cell types of different origin in the proteinatlas.org database.
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Figure 2: Effect of saracatinib on osteoclast differentiation and function. A. MTT assay of RAW264.7 cells incubated with a 
range of saracatinib concentrations (n=6 experiments). N.S.: not significant compared to controls. B. Representative images of TRAP-stained 
RAW264.7 osteoclast cultures incubated with a range of saracatinib concentrations. Red arrows indicate pseudopodia (40x magnification, 
inserts 400x). C. Quantification of RAW264.7 osteoclast numbers per well (N.Oc/well) following RANKL (R) stimulation and incubation 
with saracatinib (S) (n=3 experiments, *: p<.0.05, **: p<0.01, ***: p<0.001). D. Representative images of TRAP-stained primary murine 
osteoclast (mOCL) cultures incubated with a range of saracatinib concentrations (40x magnification, inserts 400x). E. Quantification of 
primary mOCL numbers per well (N.Oc/well) following RANKL (R) stimulation and incubation with saracatinib (S) (n=4 experiments, 
*: p<.0.05, ***: p<0.001). F. mRNA expression levels of RAW264.7 osteoclast markers determined by qPCR. Controls represent cultures 
not stimulated with any cytokine. (n=3 experiments, *: p<.0.05, **: p<0.01, ***: p<0.001). G. Representative images of resorption pits 
generated by RAW264.7 osteoclasts incubated with a range of saracatinib concentrations (40x magnification). H. Quantification of the 
number of resorption pits per field of view (N. pits/FOV) (n=3 experiments, ***: p<0.001) and I. average pit size (n=3 experiments, ***: 
p<0.001) in RAW264.7 osteoclast cultures. J. Representative images of resorption pits generated by primary mOCLs treated with DMSO or 
1 μM saracatinib (40x magnification). K. Quantification of the number of resorption pits per field of view (N. pits/FOV) (n=3 experiments, 
**: p<0.01) and (L) average pit size (n=3 experiments, **: p<0.01) in primary mOCL cultures. M. Representative confocal microscopy 
images of phalloidin-FITC staining of actin in RAW264.7 osteoclast cultures. Red arrows indicate actin rings in polarized osteoclasts. Blue: 
DAPI nuclear stain (200x magnification). All data are represented as mean +/- standard error.
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Saracatinib does not influence myeloma cell 
proliferation or bone marrow plasmocytosis in 
murine multiple myeloma models
We first determined the effect of saracatinib on the 
proliferation of MM cell lines. We found that saracatinib 
only hampers murine 5TGM.1 MM cell proliferation at 
concentrations of 5 μM or higher (Figure 4A). Similar 
effects were observed on human U266, JJN-3 and LP-1 
myeloma cell lines and murine 5T33 cell proliferation was 
Figure 3: Effect of saracatinib on osteoblast function. A. MTT assay on MC3T3-E1 cells incubated with a range of saracatinib 
concentrations (n=3 experiments, **: p<0.01, ***:p<0.001 compared to DMSO-treated control cultures). B. MTT assay on primary murine 
MSCs (mMSC) incubated with a range of saracatinib concentrations (n=3 experiments, no significant differences compared to DMSO-treated 
control cultures). C. Representative brightfield (200x magnification), Sirius red staining and von Kossa staining images (40x magnification) on 
MC3T3-E1 and mMSCs cultured in osteoblast differentiation medium (OB medium) with or without saracatinib (S). D. Quantification of Sirius 
red staining (percentage area) in osteoblast cultures (n=3 experiments, **: p<0.01). E. Quantification of von Kossa staining (percentage area) 
in osteoblast cultures (n=3 experiments, ***: p<0.001). F. Migration rates of MC3T3-E1 cells treated with a saracatinib (S) (n=3 experiments, 
***: p<0.001). G. mRNA expression levels of MC3T3-E1 osteoblast markers determined by qPCR. Controls represent cultures in standard 
medium. (n=3 experiments, *: p<.0.05, **: p<0.01, ***: p<0.001). All data are represented as mean +/- standard error.
Oncotarget30717www.impactjournals.com/oncotarget
not affected by saracatinib (Supplementary Figure S2). 
Thus, saracatinib has no effect on MM cell proliferation at 
the pharmacologically relevant saracatinib concentration 
of 1 μM or lower. In addition, we performed combination 
studies in which saracatinib was combined with drugs 
that are part of standard care for MM, i.e. bortezomib, 
lenalidomide and dexamethasone. Similarly, we could 
observe no additive or synergistic effects when combining 
saracatinib with these drugs (Figure 4A and Supplementary 
Figure S2). Next, we assessed the efficacy of saracatinib 
to hamper MM development in vivo in 2 different murine 
models. In the 5TGM.1 model, daily treatment was initiated 
one day after injection of 5TGM.1 cells and continued 
during the course of the disease (Figure 4B). BM infiltration 
by MM cells in saracatinib-treated mice (37+-6.28%) was 
not different from that in vehicle-treated mice (25.24+-
6.67%) (Figure 4C). In addition, there was no difference 
in spleen weight between saracatinib- and vehicle-treated 
mice (Figure 4D). In the 5T2MM model, daily treatment 
was initiated 5 weeks after injection of 5T2MM cells 
(Figure 4E). At this moment, a monoclonal paraprotein 
could be detected in the serum of diseased mice and the 
treatment schedule corresponds to the clinical situation 
where treatment is started upon diagnosis. Similar to the 
findings in the 5TGM.1 model, we observed no effect on 
BM infiltration by MM cells (26.10+-7.71% vs. 29.08+-
6.35%) (Figure 4F) or on spleen weight (Figure 4G). In 
conclusion, saracatinib did not hamper the proliferation 
of MM cells in the BM. Of note, we observed an almost 
complete absence of any sign of paraplegia, caused by 
spinal cord compression by tumor masses or vertebral 
collapse, in saracatinib-treated mice in the 5TGM.1 model 
at the moment of sacrifice (data not shown), suggesting 
improved bone strength in these mice.
Figure 4: Effect of saracatinib, and combinations with standard drugs, on multiple myeloma cell proliferation, and bone 
marrow plasmocytosis. A. MTT assays on 5TGM.1 myeloma cells treated with saracatinib (S), bortezomib (bor), lenalidomide (len), 
dexamethasone (dex) or combinations of saracatinib with these drugs. Drug concentrations and significance levels of single drug treatments compared 
to controls are noted on the X-axis. Significance of drug combinations compared to controls are noted near the data points in the figure (in red). No 
significant synergistic or additive effects were detected (n=3 experiments, *: p<.0.05, **: p<0.01, ***: p<0.001). B. Saracatinib treatment schedule 
in the 5TGM.1 cohort. C. Percentage BM infiltration of MM cells in naive controls, vehicle- and saracatinib (S)-treated mice in the 5TGM.1 cohort 
(n=3/7/6 bones, *: p<.0.05, **: p<0.01) as determined by FACS. D. Spleen weight as measured at the time of sacrifice in the 5TGM.1 cohort (n=3/7/6 
spleens, **: p<0.01). E. Saracatinib treatment schedule in the 5T2MM cohort. F. Percentage BM infiltration of MM cells in naive controls, vehicle- 
and saracatinib (S)-treated mice in the 5T2MM cohort (n=8/11/10 bones, *: p<.0.05, **: p<0.01) as determined on cytosmears. G. Spleen weight 
as measured at the time of sacrifice in the 5T2MM cohort (n=8/11/10 spleens, ***: p<0.001). All data are represented as mean +/- standard error.
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Saracatinib treatment limits the development 
of osteolytic bone disease in the 5TGM.1 and 
5T2MM multiple myeloma models
The effect of saracatinib treatment on trabecular 
and cortical bone parameters in myeloma-bearing mice 
was assessed by μCT. We tested saracatinib in both 
the 5TGM.1 model and the 5T2MM model. Cortical 
perforations were readily visible on radiographs (Figure 
5A and 6A).
In the 5TGM.1 model, saracatinib treatment resulted 
in a decrease in the number (Figure 5B) and size (Figure 
5C) of cortical perforations. Although perforations were 
observed in every portion of the bone, they predominantly 
occurred at the metaphyses. Next, we assessed trabecular 
bone parameters (Figure 5D) and found that trabecular 
bone volume (Tb. BV/TV) (Figure 5E) was not only 
restored, but exceeded that of naïve control mice. This was 
due to a restoration of trabecular number (Tb.N) (Figure 
5F) and trabecular thickness (Tb.Th) (Figure 5G) to levels 
observed in naive control mice following saracatinib 
treatment. In addition, connectivity density (Conn.Dn) 
(Figure 5I) values were restored. Conversely, there was 
no significant effect on trabecular separation (Tb.Sp) 
(Figure 5H). As for cortical bone parameters, we found no 
effect of saracatinib on cortical bone volume (Ct. BV/TV) 
(Figure 5J and 5K). Although cortical thickness (Ct.Th) 
was slightly restored by saracatinib treatment (Figure 5L), 
it did not reach the level of that observed in healthy mice. 
The marrow area, endosteal and periosteal perimeter were 
lower in MM bearing mice and saracatinib treatment did 
not affect these parameters (Supplementary Figure S3A).
In the 5T2MM model there was no effect of 
saracatinib treatment on the number (Figure 6B) or size 
(Figure 6C) of cortical perforations and, similar to the 
5TGM.1, these perforations occurred predominantly at 
the metaphyses. However, even though the osteolytic 
bone disease is more severe in this model (Figure 6D), 
we observed a complete restoration of Tb. BV/TV 
(Figure 6E) in the saracatinib-treated group compared 
to vehicle-treated controls. In this model, the restoration 
of Tb. BV/TV was due to an increase in Tb.N (Figure 
6F) and not Tb.Th (Figure 6G). Tb.Sp (Figure 6H) was 
restored and Conn.Dn (Figure 6I) was not affected by 
saracatinib treatment. Similar to the occurrence of cortical 
perforations, we found no effect of saracatinib treatment 
on Ct. BV/TV (Figure 6J and 6K) or Ct.Th (Figure 6L) in 
this model. Similar to the 5TGM.1 model, we observed 
no differences in porosity, marrow area, periosteal and 
endosteal perimeter between vehicle- and saracatinib-
treated myeloma-bearing mice (Supplementary Figure 
S3B).
Finally, histomorphometric analyses were performed 
on femurs from mice from the 5TGM.1 cohort. Toluidine 
blue, aniline blue (Figure 7A), Goldner’s trichrome (Figure 
7B) and TRAP stainings (Figure 7C) were performed to 
assess osteoid surface (OS/BS) and osteoblast surface 
(Ob.S/BS), and osteoclast surface (Oc.S/BS) and 
osteoclast number (Oc.N/TV) respectively. As expected, 
myeloma-bearing mice showed a decrease in OS/BS 
(Figure 7D) and Ob.S/BS (Figure 7E) compared to naive 
controls. Consistent with our in vitro data, saracatinib 
treatment did not result in a restoration of either of these 
parameters. Conversely, osteoclast surface (Figure 7F) and 
number (Figure 7G) were increased in myeloma-bearing 
mice. Although this did not reach statistical significance, 
saracatinib treatment resulted in a trend towards a decrease 
in both parameters.
DISCUSSION
Even though considerable therapeutic advances 
have been made in recent years, MM remains an incurable 
hematological malignancy associated with high morbidity 
and mortality related to osteolytic bone disease. The 
characteristic bone loss and lytic lesions are caused by 
increased osteoclastogenesis and impaired osteoblast 
function. The finding that SRC plays an important role in 
osteoclast biology and has been implicated in osteoblast 
differentiation makes SRC a promising target for the 
treatment of MM-associated osteolytic bone disease.
SRC is constitutively expressed at high levels only 
in cells that are specialized for regulated secretion, i.e. 
neuronal cells, platelets and osteoclasts [10, 25]. Also, 
SRC is predominantly maintained in an inactive state 
in normal cells. Conversely, SRC levels or activity are 
increased in many types of cancer and SRC modulates 
several aspects of tumorigenesis, including tumor 
cell adhesion, migration, motility and survival [26]. 
This spurred the development of a wide range of SRC 
inhibitors, several of which are currently in clinical 
trials or are already approved for cancer therapy [26, 
27]. Saracatinib is an orally available ATP-competitive 
SRC (IC50: 2.7 nM) inhibitor that also potently inhibits 
other SFKs members (IC50: 4-11nM) and ABL (IC50: 
30nM) [23]. Although less potent in cell-free assays 
than inhibitors such as dasatinib, saracatinib has a higher 
selectivity for SRC and it is the first inhibitor to show 
inhibition of the SRC signaling pathway in human tumor 
tissue [28]. Moreover, initial studies indicate saracatinib is 
generally well-tolerated [29-31].
Osteoclast differentiation as well as their activity 
is increased in the MM microenvironment. This is 
mediated by cytokines, e.g. RANKL and macrophage 
colony-stimulating factor (M-CSF), which are secreted 
both by MM and stromal cells [6, 32]. SRC levels are 
high in mature osteoclasts and SRC mediates signaling 
downstream from αvβ3 integrin, resulting in osteoclast 
polarization, RANK and the M-CSF receptor c-fms 
[33, 34]. De Vries et al. demonstrated that saracatinib 
reduces phosphorylated SRC levels in human osteoclast 
cultures, resulting in a reduced osteoclast differentiation 
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Figure 5: Effect of saracatinib treatment on the development of bone disease in the 5TGM.1 multiple myeloma model. 
A. Representative distal femur radiographs of naive control mice, vehicle-treated myeloma-bearing mice and saracatinib (S)-treated myeloma-
bearing mice. Red arrows indicate cortical perforations. B. Quantification of the number of cortical perforations (n=6/7/7 bones, *: p<.0.05, 
***: p<0.001). C. Quantification of perforation size (n=6/7/7 bones, *: p<.0.05, ***: p<0.001). D. Representative reconstructed 3D-models of 
trabecular bone of the proximal tibia in naive control mice, vehicle-treated mice and saracatinib-treated mice. Left panels show a top-down view, 
right panels show a lateral view. E. Trabecular bone volume (Tb.BV/TV), F. trabecular number (Tb.N), G. trabecular thickness (Tb.Th), H. 
trabecular separation (Tb.Sp) and I. connectivity density (Conn.Dn) as determined by μCT morphometric analysis on proximal tibiae (n=6/7/7 
bones, *: p<.0.05, **: p<0.01, ***: p<0.001). J. Representative reconstructed 3D-models of cortical bone of the distal femur in naive control 
mice, vehicle-treated mice and saracatinib-treated mice. K. Cortical bone volume (Ct. Bv/TV) and L. cortical thickness (Ct.Th) as determined 
by μCT morphometric analysis on distal femurs (n=6/7/7 bones, *: p<.0.05, ***: p<0.001). All data are represented as mean +/- standard error.
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Figure 6: Effect of saracatinib treatment on the development of bone disease in the 5T2MM multiple myeloma model. A. 
Representative distal femur radiographs of naive control mice, vehicle-treated myeloma-bearing mice and saracatinib (S)-treated myeloma-
bearing mice. Red arrows indicate cortical perforations. B. Quantification of the number of cortical perforations (n=8/12/10 bones, *: p<.0.05). 
C. Quantification of perforation size (n=8/12/10 bones, *: p<.0.05, **: p<0.01). D. Representative reconstructed 3D-models of trabecular bone 
of the proximal tibia in naive control mice, vehicle-treated mice and saracatinib-treated mice. Left panels show a top-down view, right panels 
show a lateral view. E. Trabecular bone volume (Tb.BV/TV), F. trabecular number (Tb.N), G. trabecular thickness (Tb.Th), H. trabecular 
separation (Tb.Sp) and I. connectivity density (Conn.Dn) as determined by μCT morphometric analysis on proximal tibiae (n=8/12/10 bones 
, *: p<.0.05, **: p<0.01). J. Representative reconstructed 3D-models of cortical bone of the distal femur in naive control mice, vehicle-treated 
mice and saracatinib-treated mice. K. Cortical bone volume (Ct. Bv/TV) and L. cortical thickness (Ct.Th) as determined by μCT morphometric 
analysis on distal femurs (n=8/12/10 bones, ***: p<0.001). All data are represented as mean +/- standard error.
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Figure 7: Histomorphometric analysis of bone parameters in the 5TGM.1 multiple myeloma model. A. Representative 
images of aniline blue stained bone sections from naive control mice, vehicle-treated myeloma-bearing mice and saracatinib (S)-treated 
myeloma-bearing mice (n=5/7/7 bones) (40x magnification). B. Representative images of Goldner’s trichrome stained bone sections from 
naive control mice, vehicle-treated mice and saracatinib-treated mice (n=5/7/7 bones) (40x magnification). C. Representative images of 
bone sections from naive control mice, vehicle-treated mice and saracatinib-treated mice stained for TRAP-positive cells. Red arrows 
indicate osteoclasts (n=3/5/4 bones) (200x magnification). D. Osteoid surface (OS/BS), E. osteoblast surface (Ob.S/BS), F. osteoclast 
surface (Oc.S/BS) and G. osteoclast number (N.Oc/TV) were measured on these sections using the Bonolab software package (*: p<.0.05, 
**: p<0.01). All data are represented as mean +/- standard error.
Oncotarget30722www.impactjournals.com/oncotarget
and function, although without such an effect on 
PBMC-derived osteoclasts in monoculture [35]. We 
confirmed several of these findings in murine primary 
and RAW264.7 osteoclast cultures and expanded on them 
(Figure 2). Saracatinib did not hamper the proliferation or 
survival of RAW264.7 cells. In accordance with previous 
reports [35-37], we observed an inhibition of osteoclast 
differentiation, polarization and matrix resorption 
following SRC inhibition, which corresponded with a 
decrease in cathepsin K (Ctsk) levels. Of note, even 0.1 μM 
saracatinib almost completely blocked matrix resorption. 
Also, saracatinib induced a decrease in dendrocyte 
expressed seven transmembrane protein (DC-Stamp) 
expression and an increase in matrix-metalloproteinase 
9 (Mmp9) expression, suggesting these osteoclasts are 
stuck in a pre-fusion state, with the presence of many 
pseudopodia, since DC-STAMP mediates osteoclast 
progenitor fusion [38] and, although not yet studied in the 
context of osteoclastogenesis, MMP9 has been implicated 
in the migration of monocytes [39, 40] and accumulates 
at the leading edge of pseudopodia [41, 42]. Defective 
osteoclast function after saracatinib treatment is in 
agreement with findings in phase I trials. Hannon et al. 
reported a decrease in bone resorption markers in healthy 
men and in patients with diverse advanced malignancies 
after saracatinib treatment [29, 30]. In addition, osteoclast 
function is impaired in Src-/- mice [16], which display an 
osteopetrotic phenotype with an inability of osteoclasts to 
form ruffled borders [43].
Osteoblast differentiation is suppressed in the 
MM microenvironment [6] and SRC protein levels have 
previously been shown to decrease during osteoblast 
differentiation [13, 14]. Here, we detected no differences 
in Src mRNA expression in mature osteoblasts compared 
to progenitor cells. Whether this is due to a different 
source of the cells or reflects a translational regulation of 
SRC in osteoblasts remains to be studied. Decreased Src 
expression inhibits immature osteoblast proliferation but 
enhances osteoblast differentiation, with a corresponding 
increase in nodule mineralization [15], which was also 
observed following dasatinib treatment of MC3T3-E1 
derived osteoblasts [44]. We observed a strong decrease in 
collagen deposition following treatment of murine primary 
and MC3T3-E1 osteoblasts with 1 μM saracatinib, which 
could not be solely attributed to a decrease in osteoblast 
numbers (Figure 3). Similarly, matrix mineralization 
pattern or amount was affected by saracatinib. 
Interestingly, a similar large increase in von Kossa staining 
intensity was observed previously in SRC-knockdown 
or -deficient primary osteoblasts [15, 44]. Finally, we 
found saracatinib dose-dependently inhibits MC3T3-E1 
migration, which corresponds with an inverse correlation 
between osteoblast migration and differentiation [45, 
46]. It is currently not clear by which mechanism SRC 
inhibition leads to these effects and further studies are 
needed to address this. Peruzzi et al. have shown that 
SRC is involved in a regulatory loop together with IL-6 
and insulin-like growth factor 5 (IGFBP5) maintaining 
osteoblasts in an immature state [14]. Multiple studies 
have reported an altered expression of osteoblast markers 
following SRC depletion or inhibition [13, 15, 44]. Here, 
we show that saracatinib treatment did not alter Src, Alp 
or Runx2 expression levels. The latter is in agreement with 
the role of SRC as a modulator of RUNX2 activity rather 
than expression [47]. On the other hand, osterix (Osx), 
which has been implicated in the regulation of alpha-1 
type 1 collagen (COL1A1) transcription [48], osteocalcin 
(Ocn), and Col1a1 expression were decreased, although 
the latter did not reach significance.
The SFK LYN has been implicated in IL-6 driven 
proliferation of CD45+ MM cells [49] and has a high 
mRNA expression level in patient-derived MM cells, while 
other SFKs including SRC are expressed at low levels 
(Figure 1). We observed no direct effect of saracatinib 
at pharmacological relevant concentrations on the 
proliferation of murine and human MM cell lines, which 
display varying degrees of IL-6 dependency and CD45 
expression [50-52]. In addition, we found no additive or 
synergistic effects of saracatinib when combined with 
bortezomib, lenalidomide or dexamethasone (Figure 4 and 
Supplementary Figure S2). This is contrary to dasatinib, 
which had minimal single agent activity in a phase 2 trial 
[53], but displayed synergy with bortezomib, melphalan 
en thalidomide in preclinical studies [54]. In vivo, when 
given in a prophylactic (5TGM.1) or in a therapeutic 
(5T2MM) setting, saracatinib did not result in a decreased 
tumor burden. This contrasts with findings in breast cancer 
bone metastasis, where SRC is critical for the survival and 
outgrowth of malignant cells in the BM [55].
Next, we assessed the effect of saracatinib on 
the development of MM-associated osteolytic bone 
disease (Figure 5 and 6). In both the 5TGM.1 and the 
5T2MM model we observed a marked prevention of 
bone loss after saracatinib treatment, with trabecular 
bone volume and number restored to levels observed in 
healthy mice. Trabecular thickness and separation were 
differentially affected during MM development in the 
5TGM.1 and 5T2MM models, which likely reflects the 
different development rate of MM as well as the different 
dependency of MM cells on, and thus interactions with, 
the BM microenvironment in these models. This could 
also explain the difference in both the number and size of 
cortical lesions during MM development in both models. 
In the 5TGM.1 model, saracatinib treatment decreased 
the number and size of cortical perforations and partially 
restored cortical thickness. However, saracatinib did not 
have such an effect in the 5T2MM model while other 
therapeutic strategies, both directed at inhibiting osteoclast 
activity [56, 57] or at promoting osteoblast differentiation 
[58], did. This is unlikely due to the delay in the start of 
treatment of these mice, considering serum paraprotein 
levels start to increase at 7-8 weeks in the 5T2MM 
Oncotarget30723www.impactjournals.com/oncotarget
model after which osteolytic bone disease develops [59]. 
Alternatively, the treatment time could have been too short 
to observe effects on cortical bone given its remodeling 
rate is slower compared to trabecular bone. Finally, we 
performed histomorphometrical analyses (Figure 7). 
Saracatinib did not prevent the reduced bone formation 
observed in myeloma-bearing mice. Of note, the decreased 
collagen secretion following saracatinib treatment we 
observed in vitro did not result in a further decrease in 
osteoid surface in vivo. Our findings are in agreement 
with the model that reduced bone formation in MM 
mainly occurs through the inhibition of Wnt-signaling in 
osteoblasts by factors such as DKK-1 and sclerostin. Both 
osteoclast surface and numbers did not differ between 
naive healthy mice and saracatinib-treated myeloma-
bearing mice. Although there is a definite trend towards 
a decrease in these 2 parameters in saracatinib- compared 
to vehicle-treated myeloma-bearing mice, this did not 
reach significance. It is possible that this is related to the 
high degree of variation in BM infiltration of MM cells, 
and thus osteoclastogenesis, between individual mice. 
In addition, this could be explained by a compensatory 
mechanism in the BM microenvironment that is not 
present in in vitro cultures. Similar to the phenotype 
observed in Src-/- mice [43], saracatinib could only block 
bone matrix resorption while osteoclast differentiation 
capacity is maintained in this more complex setting.
Although previous studies support a strong 
interdependency between MM cells and osteoclast activity 
[6, 60], we did not observe a decrease in tumor burden 
following saracatinib treatment in either model even 
though bone loss was prevented. This is in agreement 
with previous studies in which either a complete lack of, 
or an insignificant trend towards, a decrease in MM tumor 
burden was reported following successful treatment of 
bone disease, and this both in the 5TGM.1 [61, 62] and 
the 5T2MM models [56, 58]. Conversely, other studies 
do report anti-MM effects following successful treatment 
of bone disease [5, 63-65]. Thus, additional studies 
are needed to further elucidate the interplay between 
osteolytic bone disease and MM tumor growth and to 
distinguish between direct and indirect effects.
This study further establishes SRC inhibition as a 
promising approach for the treatment of MM-associated 
osteolytic bone disease. Furthermore, such a strategy 
might also be beneficial for the treatment of metastasis-
induced bone disease. We show that saracatinib treatment 
results in a prevention of bone loss in 2 murine MM 
models. Additional clinical trials with SRC inhibition 
in cancer-induced bone disease are currently ongoing, 
including SarCaBon (clinicaltrials.gov: NCT02085603), 
a phase II trial to evaluate efficacy of saracatinib for the 
treatment of cancer-induced bone pain. Bone turnover will 
be assessed as a secondary outcome measure in this trial. 
Our study warrants direct evaluation of bone parameters 
and disease progression in MM patients treated with 
saracatinib or with novel compounds with a similar SRC 




Saracatinib (AZD0530) was kindly provided 
by AstraZeneca (Macclesfield, UK). For in vivo 
studies, saracatinib was dissolved in a 0.5% 
hydroxypropylmethylcellulose solution containing 0.1% 
tween-80 (both from Sigma-Aldrich, St. Louis, USA). 
Mice received daily doses of 25 mg/kg saracatinib or 
vehicle solution by oral gavage. For in vitro studies, a 
stock solution was prepared at 10 mM in tissue-culture 
grade dimethylsulfoxide (Sigma-Aldrich).
Cell lines culture
RAW264.7 and 5TGM.1GFP+ cells (kindly 
provided by dr. G Mundy, Vanderbilt University, 
Nashville, TN, USA) were cultured in DMEM (Lonza, 
Verviers, Belgium), supplemented with 10% fetal bovine 
serum (FBS)(Sigma-Aldrich), 2 mM L-glutamine (Lonza) 
and 1% penicillin/streptomycin (P/S)(Lonza). MC3T3-E1 
cells were cultured in αMEM (Lonza) supplemented with 
10% FBS and 1% P/S. JJN-3, LP-1, U266 and 5T33 [66] 
cells were cultured in RPMI-1640 (Lonza) supplemented 
with 10% FBS, 2 mM L-glutamine and 1% P/S. Cell 
culture was performed at standard conditions (37°C/5% 
CO2). Unless otherwise indicated all cell lines were 
purchased from ATCC (Molsheim, France).
SRC family kinase expression analysis
GEO2R analysis of publically available microarray 
data was carried out to examine the expression of 
SFKs targets of saracatinib in MM patients and healthy 
controls (GSE6477) [67] and during primary murine 
osteoclast (GSE57468) [68] and primary human 
osteoblast (GSE28205) differentiation. Data acquisition 
and normalization methods in these datasets has been 
described previously [67, 68]. The data on SFKs mRNA 
expression in MM patients was supplemented with 
publically available data on protein expression in MM cell 
lines (www.proteinatlas.org) [69].
In vitro osteoclast differentiation, TRAP staining 
and actin staining
Tibias and femurs from C57/KaLwRij mice were 
flushed, the cells subjected to ficoll separation (Sigma-
Aldrich) and mononuclear cells were cultured for 3 days 
in αMEM/10% FBS/1% P/S supplemented with 100 ng/ml 
recombinant murine M-CSF (Prepotech, London, UK). The 
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monocytes were re-seeded on day 4 at a density of 6500 
cells/cm2 and 100 ng/ml recombinant murine sRANKL 
(Prepotech) was added to the culture medium to induce 
osteoclast differentiation. The medium was refreshed on day 
7 and cultures were stopped on day 10. RAW264.7 cells 
were seeded at a density of 30,000 cells/cm2 in αMEM/10% 
FBS/2 mM L-glutamine/1% P/S and 30 ng/ml recombinant 
murine sRANKL (Prepotech, London, UK). On day 3, the 
differentiation medium was refreshed and on day 4 the 
cultures were stopped. At the end of osteoclast cultures, 
cells were fixed in 4% paraformaldehyde, lysed for RNA 
extraction or stained for TRAP activity using the Leukocyte 
Tartrate-Resistant Acid Phosphatase kit (Sigma-Aldrich) 
according to the supplier’s protocol. Actin ring formation 
was assessed by staining cultures with phalloidin-FITC 
(Sigma-Aldrich) followed by analysis on a Nikon A1R 
confocal fluorescent microscope (Nikon Instruments 
Europe, Amsterdam, the Netherlands)
Osteoclast resorption assay
To assess the resorptive capacity of osteoclasts 
3000 primary monocytes or 10,000 RAW264.7 cells were 
seeded on Osteo Assay 96 well plates (Corning, New 
York, USA) in osteoclast differentiation medium. The 
medium was refreshed every 3 days. After 12 days, a Von 
Kossa staining was performed to visualize non-resorbed 
matrix (see later). The number of resorption pits and 
average pit size were quantified using ImageJ software 
(NIH, Bethesda, USA).
In vitro osteoblast differentiation
Primary murine BM derived MSCs were isolated 
as described previously [70] and seeded at a density of 
12,500 cells/cm2. To induce osteoblast differentiation, 
confluent MSCs were cultured in αMEM/10% FBS/2 mM 
L-glutamine/1% P/S supplemented with 50 μg/ml ascorbic 
acid (Sigma-Aldrich) and 2 mM β-glycerolphosphate 
(Sigma-Aldrich) for 28 days. The differentiation medium 
was refreshed every 3 days. MC3T3-E1 cells were seeded 
at a density of 30,000 cells/cm2 in αMEM/10% FBS/1% 
P/S. After the cells reached confluence, the medium was 
supplemented with 50 μg/ml ascorbic acid and 2 mM 
β -glycerolphosphate for 14 days to induce osteoblast 
differentiation. The differentiation medium was refreshed 
every 3 days. At the end of the osteoblast cultures, the cells 
were lysed for RNA extraction or bone matrix stainings 
were performed.
Proliferation assay
Cell proliferation and viability was assessed with 
the cell proliferation kit I (Roche, Mannheim, Germany) 
according to the supplier’s protocol. In short, cultures in 
96 well plates were incubated with 10 μl MTT labeling 
reagent for 4 hours at 37°C. Next, 100 μl solubilization 
reagent was added to each well and incubated overnight at 
37°C. The next day, absorbance was measured at 570 nm 
on a Wallac 1420 Victor2 microplate reader (Perkin Elmer, 
Waltham, USA).
Osteoblast wound healing assay
To assess cell migration after treatment with 
saracatinib, MC3T3-E1 cells were seeded at a density 
of 35,000 cells/chamber in αMEM/10% FBS/1% P/S in 
silicone culture inserts (Ibidi, Martinsried, Germany). 
After 24 hours, the culture inserts were removed leaving 
a 500 μm gap in the MC3T3-E1 monolayer. Four phase-
contrast pictures of the remaining gaps were taken over 
a period of 24 hours with a TiS microscope (Nikon, 
Tokyo, Japan). The surface of the gaps was measured 
using NIS-Elements software (Nikon) and migration 
rates were calculated using linear regression analysis and 
determination of the slope.
RNA extraction, cDNA synthesis and real-time 
PCR
RNA was extracted using the RNeasy Mini kit 
(Qiagen, Venlo, the Netherlands) according to the 
supplier’s protocol. Isolated RNA samples were subjected 
to DNaseI (Roche, Vilvoorde, Belgium) digestion prior to 
determination of the purity and concentration on a ND-
1000 spectrophotometer (Thermo Scientific, Wilmington, 
USA). cDNA synthesis was performed on 100 ng RNA 
with random hexamer primers using the Transcriptor 
First Strand cDNA Synthesis Kit (Roche) according 
to the supplier’s protocol. Real-time PCR (qPCR) was 
performed on a Lightcycler 480 instrument (Roche) using 
Kapa SYBR Fast qPCR master mix (Kapa Biosystems, 
Wilmington, USA) using 250 nmol/L of the appropriate 
primers (Supplementary Table S1). Gene expression was 
normalized to β-actin and β2-microglubulin expression. 
All primers were synthesized by Integrated DNA 
Technologies (Leuven, Belgium). The cycling conditions 
were as follows: 3 min at 95°C, 40 cycles of 10 s at 
95°C, 30 s at 60°C and 1 s at 75°C followed by a melting 
curve analysis. Measurements were performed at least in 
triplicate. To compare expression levels between different 
conditions the ΔCt method was used.
Von Kossa and Sirius red staining
Von Kossa staining was performed to detect 
mineralized matrix nodules in the osteoclast resorption 
assay and in osteoblast cultures. Cultures were 
decellularized with 20 mM NH4OH (Sigma-Aldrich) for 
30 minutes at room temperature. After rinsing, plates were 
incubated with 5% AgNO3 (Sigma-Aldrich) solution for 1 
hour, rinsed, and incubated with 1% pyrogallol (Sigma-
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Aldrich) solution for 10 minutes at room temperature in 
daylight. Collagenous matrix was visualized with Sirius 
red staining. After fixation in 70% ethanol, cultures were 
rinsed and stained with 0.1% direct red (Sigma-Aldrich) 
in picric acid (Sigma-Aldrich) solution for 1 hour at room 
temperature. Both Von Kossa and Sirius red staining were 
quantified with ImageJ software.
The 5TGM.1 and 5T2MM murine multiple 
myeloma models
The 5TMM murine models originate from 
spontaneously developed MM in elderly C57BL/KalwRij 
mice [71-73]. The 5TGM.1GFP+ cell line was derived 
from 5T33MM cells [74]. The in vivo growing 5T2MM 
cells have been propagated by i.v. transfer of 2x106 
cells from diseased mice in younger syngeneic C57BL/
KalwRij mice as described previously [72, 75]. C57BL/
KalwRij mice were purchased from Harlan (Horst, the 
Netherlands). All animals had free access to food and 
tap water and they were housed and treated following 
conditions approved by the ethical committee for animal 
experiments of the University of Liege and the Vrije 
Universiteit Brussel (ULg license no. 1336 and VUB 
license no. 13-281-1). The 5TGM.1 model develops MM 
over the course of 30 days after i.v. injection of 2.5x105 
5TGM.1GFP+ cells in 200 μl serum-free DMEM medium 
in C57BL/KalwRij mice. The induced MM disease is 
characterized by a selective BM infiltration and moderate 
osteolytic bone disease. BM infiltration of MM cells in 
these mice was determined by FACS detection of GFP+ 
cells on a FACSCalibur flow cytometer (BD Biosciences, 
Erembodegem, Belgium). MM develops within 10-12 
weeks in the 5T2MM model and the disease in these mice 
is characterized by BM infiltration of 5T2MM cells and 
the occurrence of severe osteolytic lesions. In these mice, 
plasmacytosis was determined by staining cytosmears of 
the BM with May-Grunwald-Giemsa.
Treatment of multiple myeloma-bearing mice 
with saracatinib
For the 5TGM.1 cohort, 14 male mice were 
inoculated with 5TGM.1GFP+ cells at 8 weeks old. 
Of the myeloma-bearing mice, 7 were given vehicle 
solution and 7 were given 25 mg/kg/day saracatinib by 
oral gavage starting at day one after injection. Six male 
mice were included as naive tumor-free controls. For the 
5T2MM cohort, 22 female mice were injected at 8 weeks 
old and divided in a vehicle-treated myeloma-bearing 
group (n=12) and a saracatinib-treated myeloma-bearing 
group (n=10). In this cohort, 25 mg/kg/day saracatinib 
treatment was started at 5 weeks post-injection when a 
paraprotein could be detected by serum electrophoresis. 
Eight female mice were included as naive tumor-free 
controls. All mice were sex- and age-matched and they 
were sacrificed when the first mice of a cohort showed 
signs of established MM, i.e. at 4 weeks post-injection 
for the 5TGM.1 cohort and at 11 weeks post-injection for 
the 5T2MM cohort.
Micro-computed tomography
One tibia and one femur were isolated after 
sacrifice of each mouse. The bones were fixed overnight 
in 2% paraformaldehyde/PBS solution at 4°C. The next 
day, the fixation solution was replaced by PBS and the 
bones were stored at 4°C. Micro-computed tomography 
(μCT) was performed on the distal femur and proximal 
tibia with a Skyscan 1172 (Bruker, Kontich, Belgium). 
The scanner source was set at 50 kV and 200 μA, and 
a 0.5 mm aluminum filter was applied. The pixel size 
was 5 μm2. Images were captured every 0.4 degrees 
through 180 degrees of rotation using Skyscan software 
(Bruker). Reconstruction was performed with NRecon 
software (Bruker). Morphometric 3D analysis of 
trabecular bone was performed on proximal tibias on a 
1.5 mm section starting 0.5 mm from the growth plate 
using CTAnalyzer software (Bruker, version 1.14.4.1). 
Morphometric 2D and 3D analysis of cortical bone was 
performed in distal femurs on a 0.5 mm section starting 
3 mm from the growth plate. 3D images of bones were 
generated using CTVol software (Bruker). The number of 
cortical perforations was counted manually and blinded 
on radiographs.
Bone histomorphometry
Histomorphometric parameters were measured on 
femurs from mice in the 5TGM.1 cohort. Isolated femurs 
were dehydrated in ascending alcohol concentrations, 
defatted in xylene and embedded in methylmethacrylate. 
All histomorphometric parameters were recorded as 
recommended by the American Society for Bone and 
Mineral Research Histomorphometry Nomenclature 
Committee [76] and measured using the Bonolab 
software package designed for bone histomorphometry 
(Microvision, Evry, France). Osteoid surface and 
osteoblast surface were measured on sections stained 
with toluidine blue, aniline blue and Goldner’s 
trichrome (Sigma-Aldrich). Osteoclasts were detected 
by tartrate-resistant acid phosphatase (TRAP) staining 
(Sigma-Aldrich). Briefly, sections were stained for 
acid phosphatase using naphthol ASTR phosphate 
as substrate in the presence of 50 mM tartrate with 
hexazotised pararosaline, and counterstained with 
methyl green. TRAP-positive cells were counted in the 
whole epiphysis (×25), and expressed as the number 




All in vitro experiments were performed in 
triplicate. Results are shown as means +/- standard error 
and representative pictures are shown. For comparisons 
of 2 means, a Student t-test was used. For comparisons of 
multiple means, a one-way ANOVA was used, followed by a 
Dunnett’s post-hoc test (SFKs expression analysis and MTT 
assays) or Tukey’s post-hoc test (other experiments). All 
statistical analyses were performed with Prism 5 software 
(Graphpad software, La Jolla, USA). P-values below 0.05 
were considered significant and p-values are represented as 
follows: *: p<0.05, **: p<0.01, ***: p<0.001.
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